Preview

Колопроктология

Расширенный поиск

ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ УСТЕКИНУМАБА ПРИ БОЛЕЗНИ КРОНА (обзор литературы)

https://doi.org/10.33878/2073-7556-2019-18-3-119-130

Полный текст:

Аннотация

Болезнь Крона (БК) является хроническим аутоиммунным заболеванием желудочно-кишечного тракта, которое поражает, в основном, молодых людей трудоспособного возраста. До сих пор пациенты с данным заболеванием не могут быть вылечены ни с помощью консервативной терапии ни хирургическими методами. Эффективность препаратов, доступных для лечения БК, ограничена. Кроме того, их применение нередко сопровождается нежелательными явлениями. Все это рождает потребность в новых препаратах, принципиально отличающихся по механизму действия, с высокой эффективностью и хорошим профилем безопасности. Данный обзор посвящен новому биологическому препарату для лечения БК, направленному на блокирование интерлейкинов 12 и 23, которые задействованы в патогенезе воспаления при ВЗК. В обзоре представлены данные клинических испытаний препарата 2 и 3 фазы и данные, полученные в клинической практике, позволяющие делать выводы об эффективности и безопасности данного препарата, а также его месте в алгоритме лечения больных с БК.

Об авторах

М. В. Шапина
ФГБУ «ГНЦК им. А.Н. Рыжих» Минздрава России
Россия


Б. А. Нанаева
ФГБУ «ГНЦК им. А.Н. Рыжих» Минздрава России
Россия


А. В. Варданян
ФГБУ «ГНЦК им. А.Н. Рыжих» Минздрава России
Россия


Список литературы

1. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017; № 2, с. 7-29.

2. Халиф И.Л. Изменения в клинических рекомендациях по диагностике и лечению больных ВЗК. Поликлиника. 2017; 3: с. 20-26.

3. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn’s disease management: Need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6 Suppl.2:S224-234.

4. Chaparro M, Ordas I, Cabre E, Garcia-Sanchez V,et al. Safety of thiopurine therapy in inflammatory bowel disease: Long-term followup study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404-1410.

5. Domenech E, Manosa M, Navarro M, Masnou H, et al. Long-term methotrexate for Crohn’s disease: Safety and efficacy in clinical practice. J Clin Gastroenterol. 2008;42:395-399.

6. Gonzalez-Lama Y, Taxonera C, Lopez-Sanroman A, Perez-Calle JL, et al. Methotrexate in inflammatory bowel disease: A multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. Eur J Gastroenterol Hepatol. 2012;24:1086-1091.

7. Белоусова Е.А., Морозова А.Н., Никитина Н.В. Инфликсимаб (Ремикейд) в лечении рефрактерных форм болезни Крона. Российский медицинский журнал. 2006; № 1, с. 28-32.

8. Халиф И.Л., Шапина М.В. Применение ведолизумаба при воспалительных заболеваниях кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; № 6, с. 92-100.

9. Шапина М.В., Халиф, И.Л., Нанаева Б.А. Применение цертолизумаба пэгола при болезни Крона (обзор литературы). Колопроктология. 2016; № 3,с. 102-108.

10. Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies [abstract no. OP028]. J Crohns Colitis. 2016;10(Suppl 1):S23–4.

11. Ben-Horin S, Chowers Y. Review article: Loss of response to antiTNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987-995.

12. Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Transl Res. 2014;163:533-556.

13. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, et al. Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660.

14. Халиф И.Л., Шапина М.В. Биологическая (антицитокиновая) терапия при болезни Крона: эффективность и потеря ответа. Доказательная гастроэнтерология. 2013; № 3, с. 13-23.

15. Chaparro M, Panes J, Garcia V, Manosa M et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose «escalation» in patients losing response. J Clin Gastroenterol. 2011;45:113-118.

16. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: Results from the CHARM trial. Am J Gastroenterol. 2009;104:1170-1179.

17. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: A review. Am J Gastroenterol. 2009;104:760-767.

18. Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol. 2014;20: 1139-1146.

19. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397-404.

20. Lowenberg M, d’Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep. 2013;15:311.

21. Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14:583-600.

22. Simon EG, Ghosh S, Iacucci M, Moran GW. Ustekinumab for the treatment of Crohn’s disease: Can it find its niche? Therap Adv Gastroenterol. 2016;9:26-36.

23. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: New immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009;58:1152-1167.

24. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12:5606-5610.

25. Kavanaugh A, Ritchlin C, Rahman P, Puig L, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000-1006.

26. Toichi E, Torres G, McCormick TS, Chang T, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/ IL-23 in psoriasis. J Immunol. 2006;177:4917-4926.

27. Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn’s disease. Discov Med. 2012;14:253-262.

28. Cote-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P. Biologics in inflammatory bowel disease: What are the data? United European Gastroenterol J. 2015;3:419-428.

29. Schmitt H, Billmeier U, Dieterich W, Rath T, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease.Gut.2019;68(5):814-828. doi: 10.1136/gutjnl-2017-315671.

30. Benson JM, Peritt D, Scallon BJ, Heavner GA et al. Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535-545.

31. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008;57:1682-1689.

32. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719-729.

33. Инструкция по применению препарата Стелара (ЛСР-006465/09) от 12.04.19, Электронный ресурс: http://grls. rosminzdrav.ru

34. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR et al. Ustekinumab Crohn’s Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135: 1130–1141.

35. Sands BE, Feagan BG, Rutgeerts P, Colombel JF et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618-627, e613.

36. Sandborn WJ, Rutgeerts P, Gasink C et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65–77. https://doi. org/10.1111/apt.14794

37. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946-1960.

38. Shelton E, Allegretti JR, Stevens B, Lucci M et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm Bowel Dis. 2015;21:2879-2885.

39. Sands BE, Gasink C, Jacobstein D, Gao LL et al. Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn’s disease patients: Results from the IM-UNITI maintenance study. United European Gastroenterol J. 2016;4:OP005.

40. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711-721.

41. Wils P, Bouhnik Y, Michetti P, Flourie B et al. Long-term efficacy and safety of ustekinumab in refractory Crohn’s disease patients: A multicenter retrospective experience. J Crohns Colitis. 2017;11 Suppl.1: S43

42. Li K, Chan D, Pollack P, Jacobstein D, et al. Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn’s disease. Gastroenterology. 2017;152Suppl.1.:S595.

43. Battat R, Kopylov U, Bessissow T, Bitton A, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15:1427-1434.

44. Ma C, Fedorak RN, Kaplan GG, Dieleman LA, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: Real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232-1243.

45. Wils P, Bouhnik Y, Michetti P, Flourie B, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242-250.e1-2.

46. Khorrami S, Ginard D, Marin-Jimenez I, Chaparro M, et al. Ustekinumab for the treatment of refractory Crohn’s disease: The Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662-1669.

47. Kopylov U, Afif W, Cohen A, Bitton A et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience. J Crohns Colitis. 2014;8:1516-1522.

48. Gottlieb AB, Kalb RE, Langley RG, Krueger GG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441-1448.

49. Papp K, Gottlieb AB, Naldi L, Pariser D et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14:706-714.

50. Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961-969.

51. Loftus EV, Sloan S, Ramachandran P, Yang Z et al. Comparison of rates of active tuberculosis infection in the phase 2 and 3 trial programs for ANTI-IL12/23 and ANTI-TNF. Gastroenterology. 2017;1 52Suppl.1.:S596.

52. Rolston VS, Kimmel J, Hudesman D, Chang S, Bosworth BP, Popov V. Adverse events with use of ustekinumab: A systematic review and meta-analysis. Gastroenterology. 2017;152Suppl.1.:S578-579.

53. Ginard D, Khorrami S, Marín I, Chaparro M, et al. One-year outcomes of ustekinumab therapy in a multi-drug refractory Crohn’s disease cohort. ECCO. 2013:P425.

54. Kimball AB, Guenther L, de Jong E, Kalia S, et al. Pregnancy outcomes in women with moderate to severe psoriasis: The PSOLAR experience. J Am Acad Dermatol. 2015;EADV: P1781.

55. Cortes X, Borras-Blasco J, Antequera B, Fernandez-Martinez S, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: A case report and review of the literature. J Clin Pharm Ther. 2017;42:234-236.

56. Galli-Novak E, Mook SC, Buning J, Schmidt E, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e191-192.

57. Feagan B, Gasink C, Gao LL, Blank M, et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase 2 b study of ustekinumab in patients with moderately to severely active Crohn’s disease. J Crohn’s Colitis. 2012;6 Suppl. 1:S129-130.

58. Gasink C, Chan D, Gao LL, Schenkel B, Han C. Assessment of sleep impairment in patients with Crohn’s disease: Results from the Ustekinumab Certifi Study. Gastroenterology. 2013;144 Suppl. 1:S231.

59. Sands BE, Han C, Gasink C, Szapary P et al. Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe Crohn’s disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials. Gastroenterology. 2016;150 Suppl. 1:S1004.

60. Sandborn WJ, Sands BE, Gasink C, Yeager B et al. Reduced Rates of Crohn’s-Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years. Gastroenterology. 2018;154Suppl.1.:S377-378.

61. Gottlieb A, Menter A, Mendelsohn A, Shen YK, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, doubleblind, placebo-controlled, crossover trial. Lancet. 2009;373: 633-640.

62. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S et al. AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF- biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013; 145: 1459–1463.

63. Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613-623.

64. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007; 357: 239–250.

65. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А. и соавт. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018; № 12(3), с. 4-18.

66. Armuzzi A, Ardizzone S, Biancone L, et al. Ustekinumab in the management of Crohn’s disease: Expert opinion. Digestive and Liver Diseases. 2018;50(2):653-660.

67. Danese S, Bonovas S, Peyrin-Biroulet L. Positioning ustekinumab in Crohn’s disease: from clinical evidence to clinical practice. Jornal of Crohn’s and Colitis, 2017, 1-9 doi:10.1093/ecco-jcc/jjx079.

68. Pacou M, Mesana L, Gauthier A, Naessens D et al. Indirect treatment comparison of ustekinumab versus other biologics in moderate to severe Crohn’s disease: A 1-year treatment sequence analysis. Value Health. 2016;19:A576.

69. Tillack C, Ehmann LM, Friedrich M, Laubender R, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014; 63: 567–577.

70. Инструкция по применению препарата Ремикейд (П N012948/01) от 15.11.11, Электронный ресурс: http://grls. rosminzdrav.ru

71. Инструкция по применению препарата Энтивио (ЛП-003697) от 22.02.16, Электронный ресурс: http://grls.rosminzdrav.ru


Для цитирования:


Шапина М.В., Нанаева Б.А., Варданян А.В. ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ УСТЕКИНУМАБА ПРИ БОЛЕЗНИ КРОНА (обзор литературы). Колопроктология. 2019;18(3(69)):119-130. https://doi.org/10.33878/2073-7556-2019-18-3-119-130

For citation:


Shapina M.V., Nanaeva B.A., Vardanyan A.V. EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE (review. Koloproktologia. 2019;18(3(69)):119-130. (In Russ.) https://doi.org/10.33878/2073-7556-2019-18-3-119-130

Просмотров: 1013


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7556 (Print)
ISSN 2686-7303 (Online)